0001193125-26-210446
SEC filingQ1 financials showed sharply reduced losses driven by higher collaboration revenue and lower operating expenses following zerlasiran Phase 3 readiness completion in 2025, though cash burn increased amid ongoing clinical development investments.
Silence Therapeutics reported improved Q1 2026 results, with revenue of $422K marking a 197% increase from $142K in the prior year quarter, driven by steady recognition from collaboration agreements. Gross profit reached $411K, up 367% from $88K, yielding a 97% gross margin that underscores the high-margin nature of these partnership revenues, primarily from minimal cost of sales.
Operating income loss narrowed significantly to -$15.7M from -$28.4M, a 45% improvement, as the company benefited from reduced costs following completion of zerlasiran Phase 3 readiness in 2025. This decrease was largely due to lower contract manufacturing activities and contracted development costs associated with that program, along with personnel cost reductions from lower headcount. Net income followed suit, improving 48% to -$15.0M from -$28.5M, with diluted EPS advancing 45% to -$0.11 from -$0.20. These enhancements reflect disciplined cost management post key milestones, even as the company continues substantial R&D investments in its clinical pipeline.
Cash flow from operations reflected -$15.6M used, higher than the -$12.3M in Q1 2025, attributable to the absence of prior-year R&D credit receipts amid sustained development spending. With no capital expenditures this quarter (down from $4K prior year), free cash flow aligned with operating cash use at -$15.6M. Management notes that since inception, the company has incurred significant operating losses and negative cash flows, consistent with its clinical-stage biotech profile focused on research, regulatory pursuits, and product candidate advancement.
Liquidity remains a focus, with current cash and short-term investments positioned to fund forecasted operating expenses and capital needs into 2028, per management's evaluation. However, the Group anticipates continued losses for the foreseeable future and will require additional funding for clinical development. This runway provides visibility for pipeline progress, including zerlasiran and other programs, while highlighting the need for strategic partnering or financing to extend beyond 2028 amid expected R&D intensity. Overall, Q1 demonstrates operational leverage from prior investments maturing, setting a foundation for near-term milestones despite biotech's inherent loss trajectory.